BioNTech Investor Day Presentation Deck

BNT312 showed higher ability to promote DC maturation vs either monoclonal antibody or their combination % HLA-DR+/CD86+ of total DC population 60 40 20 0 11 0.001 0.0001 0.1 0.0001 0.001 0.1 ll Antibody concentration (µg/mL) BNT312 (Gen1042) is partnered with Genmab based on 50/50 sharing of costs and profits. The dotted line shows the percentage of HLA-DR+ CD86+ DCs in DC-T-cell cultures in the absence of treatment. Muik A, et al. J Immuno Ther Cancer 2022; 10:e004322. L 0.0001 0.001 0.1 Isotype ctrl bsAb-CD40* ctrl bsAb-ctrlx 4-1BB Protein therapeutics bsAb-CD40x ctrl + bsAb-ctrlx 4-1 BB Fc inert mitazalim ab analog Fc inert urelumab analog DuoBody-CD40×4-1BB BIONTECH 127

View entire presentation